11/19/2026 | Press release | Distributed by Public on 11/19/2026 03:59
Today's big story: Could Anthropic Stock Fall 25%?
Humana (HUM) stock is a bet on whether the company can keep more of its fast-growing sales as profit. The shares fell 13.0% on November 18, 2026, while the SPDR S&P 500 ETF slipped just 0.306%. The drop came after a strong year for the insurer. Humana stock returned 66.9% over the past twelve months, against 11.0% for the S&P 500. So what is a buyer paying for at today's price?
Humana Stock Trades At A Premium On Earnings
Humana stock trades at 37.2 times its earnings over the past twelve months. The S&P 500 trades at 21.5 times its earnings. This high multiple reflects how little profit the company makes. Over those twelve months, Humana kept just 0.808% of its revenue as net profit, against 13.5% for the S&P 500.
Humana kept just 0.808% of its revenue as profit, yet its stock trades at 37.2 times earnings. If those margins stay thin, your money may wait a long time for that bet to pay off. Meanwhile, the Trefis Income Solution pays a dividend yield about 3x the S&P 500's, from 50 stocks with at least 10 straight years of dividends. See what it pays.
One bad quarter explains part of the thin profit. Humana posted a net loss of $0.796 billion in the quarter ended December 31, 2025, a period included in those twelve months. Its growth, by contrast, beats the market's. Over the past three years, Humana's revenue grew 14.8% a year on average, compared with 6.5% for the S&P 500. Buyers are therefore paying a premium for a large, fast-growing insurer whose profit margin is a small fraction of the market's.
Can Humana Keep More Profit From Sales?
Humana's management expects to, and it has set its prices with that aim. On the November 6, 2026 call, management said pricing for margin was its top priority in its bids for 2027 Medicare plans. The company also raised its 2026 outlook for adjusted earnings per share to at least $9.50, from at least $9. Further out, Humana expects its plan lineup to put it on track for a margin of 3% or more in 2028. Management did not say whether that 3% is a net margin, so it may not compare directly with the net margins in this article.
Reported results have not yet turned. Humana's revenue rose 26.1% from a year earlier in the quarter ended September 30, 2026. But its net margin in that quarter slipped to 0.394%, from 0.597% a year earlier.
Costs are the clearest risk to that plan. Humana expects Part D drug costs to rise 14% to 15% in 2027, and its core medical cost growth to be slightly higher than in 2026. The company says it has priced the Part D rise into its bids. But Humana does not yet know how many of its members will stay. Management called it too early to say where the 2027 margin will land.
When Will Humana Update Its Profit Goals?
Humana will host an investor update on December 10, 2026. There, management plans to update the 2028 goals it set at its investor day in 2025. Humana is then expected to report its next quarterly results in February 2027. That report will show its net margin for the full year 2026.
So a buyer at today's price pays a premium for a margin recovery that reported results do not yet show. The November 18 trading session also showed how far Humana's shares can move in a single day. When one stock grows into a big part of a portfolio, a day like that is a reason to have an exit plan ready.
Too Much Riding On One Stock?
If Humana is a big part of your wealth, so are its risk and its tax bill. What's your exit plan? Our partner advisory firm offers a free 30-minute strategy review covering a floor under losses and a lower-tax way out.
Spot an error or want more like this? Tell us in 10 seconds.